Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

This study is testing a maintenance immunotherapy combination for people with unresectable (cannot be surgically removed) or metastatic pancreatic cancer who have already completed first-line chemotherapy and achieved stable disease or a partial response. The goal is to keep the cancer in check for longer after chemotherapy ends. **You may be eligible if...** - You are 18 or older with confirmed pancreatic cancer that cannot be removed surgically or has spread - You have completed 16–24 weeks of standard first-line chemotherapy and your cancer has not progressed - Your cancer showed at least stable disease or partial shrinkage after chemotherapy - You are able to understand the study and provide written consent **You may NOT be eligible if...** - Your cancer has progressed during or after first-line chemotherapy - Your organ function is not adequate to receive the study treatment - You do not meet other health-related requirements set by the study protocol Talk to your doctor to see if this trial is right for you.